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Abstract
Background Cancer cachexia is a metabolic disorder involving perturbed energy balance and altered mitochondrial function.
Chemotherapy is a primary treatment option for many types of cancer, but there is substantial evidence that some chemother-
apeutic agents can also lead to the development and progression of cachexia. In this study, we apply a comprehensive and
systems level metabolomics approach to characterize the metabolic perturbations in murine models of cancer-induced and
chemotherapy-induced cachexia. Knowledge of the unique pathways through which cancer and chemotherapy drive cachexia
is necessary in order to develop effective treatments.
Methods The murine Colon26 (C26) adenocarcinoma xenograft model was used to study the metabolic derangements
associated with cancer-induced cachexia. In vivo administration of Folﬁri (5-ﬂuorouracil, irinotecan, and leucovorin) was used
to model chemotherapy-induced cachexia. Comprehensive metabolic proﬁling was carried out using both nuclear magnetic
resonance-based and mass spectrometry-based platforms. Analyses included plasma, muscle, and liver tissue to provide a
systems level proﬁling.
Results The study involved four groups of CD2F1 male mice (n = 4–5), including vehicle treated (V), C26 tumour hosts (CC),
Folﬁri treated (F), and C26 tumour hosts treated with Folﬁri (CCF). Signiﬁcant weight loss including skeletal muscle was
observed for each of the experimental groups with the tumour hosts showing the most dramatic change (3.74 g vs. initial
body weight in the CC group). Skeletal muscle loss was evident in all experimental groups compared with V, with the CCF
combination resulting in the most severe depletion of quadriceps mass (38% vs. V; P < 0.001). All experimental groups were
characterized by an increased systemic glucose demand as evidenced by decreased levels of circulating glucose (47% in CC
vs. V; P < 0.001) and depletion of liver glucose (51% in CC vs. V; P < 0.001) and glycogen (74% in CC vs. V; P < 0.001). The
cancer-induced and chemotherapy-induced cachexia models displayed unique alterations in ﬂux through the tricarboxylic acid
cycle and β-oxidation pathways. Cancer-induced cachexia was uniquely characterized by a dramatic elevation in low-density
lipoprotein particles (+6.9-fold vs. V; P < 0.001) and a signiﬁcant increase in the inﬂammatory marker, GlycA (+33% vs. V;
P < 0.001).
Conclusions The results of this study demonstrated for the ﬁrst time that cancer-induced and chemotherapy-induced
cachexia is characterized by a number of distinct metabolic derangements. Effective therapeutic interventions for cancer-
induced and chemotherapy-induced cachexia must take into account the speciﬁc metabolic defects imposed by the
pathological or pharmacological drivers of cachexia.
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Introduction
As patients with cancer progress along their disease trajec-
tory, it is common for them to be afﬂicted by the severe
wasting syndrome known as cancer-induced cachexia. In
some cancers, the prevalence of cachexia in the advanced
stages is nearly 80%, and the consequences of this wasting
will be the ultimate cause of mortality in ~30% of patients.1,2
Cachexia is distinct from starvation, age-related loss of
muscle mass (often referred to as sarcopenia), anorexia,
malabsorption, and hyperthyroidism.3
There is an increasing recognition that cancer cachexia is a
metabolic disorder involving perturbed energy balance and
altered mitochondrial function.4–8 The major drivers of these
dysfunctions are an extreme inﬂammatory response and
impaired signalling related to muscle protein turnover.1
Although cachexia is often accompanied by reduced food
intake and anorexia, it is clearly distinct from starvation,
and the alterations to energy metabolism cannot be
corrected by increased nutritional intake alone.1
One of the ﬁrst lines of treatment for cancer patients
is often chemotherapy, but there is increasing evidence
that some chemotherapeutic agents actually contribute
to the development and progression of cachexia. Studies
in healthy rats have demonstrated that chemotherapeutic
agents including cyclophosphamide, 5-ﬂuorouracil, cis-
platin, and methotrexate induce a negative nitrogen bal-
ance and commensurate weight loss.9 Daumrauer et al.
reported that cisplatin, CPT-11, adriamycin, and etoposide
lead to muscle wasting via activation of NF-κB but are in-
dependent of the usual cancer-associated up-regulations
in the ubiquitin proteasome system.10 Studies from our
laboratory using the combination therapy Folﬁri (5-ﬂuoro-
uracil, leucovorin, and irinotecan) have shown that
wasting is dependent upon activation of ERK1/2 and p38
mitogen-activated protein kinases pathways but is inde-
pendent of the ubiquitin proteasome system.6 In contrast,
another study of cisplatin demonstrated an up-regulation
of myostatin and the ubiquitin proteasome system.11,12
Oxidative stress has also been identiﬁed as a consequence
of a number of chemotherapeutic agents, which could in-
duce muscle wasting via mitochondrial dysfunc-
tion.5,6,10,13,14 These studies highlight the complexity of
the muscle wasting effects of chemotherapy and suggest
that more detailed studies are needed to deconvolve
the mechanisms that drive both cancer-associated and
chemotherapy-induced cachexia.
Given the profound metabolic derangements that accom-
pany cachexia, there has been a surprising paucity of de-
tailed metabolomics investigations in this area. The
advantage of a metabolomics approach is that an individ-
ual’s metabolic state represents the combined inﬂuences
of age, genetics, diet, environmental exposures, and dis-
ease state. As such, it more closely represents the
functional phenotype of the individual. In one of the earli-
est metabolomics studies of cachexia, the mouse Colon26
(C26) adenocarcinoma model demonstrated distinct alter-
ations in glucose and lipid metabolism.15 A later study
using the same murine model clariﬁed that the serum
metabolome of cachexia was clearly distinct from the
effects of starvation or tumour burden.16 A more recent
metabolomics study in an aggressive cachexia-inducing
kidney cancer model found that tumour-secreted factors
induce excessive fatty acid oxidation leading to oxidative
stress, p38 activation, and impaired muscle growth.17 To
date, there have been no metabolomics investigations into
the metabolic pathways involved in chemotherapy-induced
cachexia.
In this study, we applied a comprehensive and systems level
metabolomics approach to investigate the similarities and
differences between cancer-induced and chemotherapy-
induced cachexia. Our analytical approach involved three
separate platforms selected to provide detailed coverage
of the major energetic pathways. The nuclear magnetic
resonance (NMR) platform detected a wide range of me-
tabolites including those from glycolysis, the tricarboxylic
acid (TCA) cycle, and amino acid metabolism. The targeted
mass spectrometry platform was selected to provide details
on lipid metabolism. Lastly, an NMR-based lipoprotein anal-
ysis was selected to provide details on a range of lipopro-
tein particle sizes and numbers relating to lipid and
cholesterol metabolism. In order to provide a more holistic
evaluation of energy metabolism, we analysed not only
blood plasma but also muscle and liver tissue. Our study
utilizes the well-established C26 colorectal tumour model
of cancer cachexia and treatment with Folﬁri as a model
of chemotherapy-induced cachexia.
Materials and methods
Animals
All animal experiments were conducted with the approval of
the Institutional Animal Care and Use Committee at Indiana
University School of Medicine and were in compliance with
the National Institutes of Health Guidelines for Use and Care
of Laboratory Animals and with the ethical standards laid
down in the 1964 Declaration of Helsinki and its later amend-
ments. For this study, we used 8-week-old CD2F1 male mice
(Harlan, Indianapolis, IN, USA). The animals were maintained
on a regular dark–light cycle (light from 8 a.m. to 8 p.m.),
with free access to food and water during the whole experi-
mental period. Mice were divided randomly into four groups:
mice inoculated with vehicle (V; saline), serving as controls
(n = 4) and animals treated with Folﬁri (F; n = 5). For the
tumour-bearing animals (CC), 10 mice were injected
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intrascapularly (s.c.) with 1 × 106 C26 adenocarcinoma cells in
sterile saline, treated or not with Folﬁri (CCF).18 The two
groups administered with Folﬁri received twice a week com-
bination of 5-ﬂuorouracil (50 mg/kg), leucovorin (90 mg/kg),
and CPT-11 (24 mg/kg) intraperitoneal (i.p.) starting at
Day 5 after tumour injection (all drugs were purchased
from Sigma-Aldrich, St. Louis, MO, USA). Based on previous
ﬁndings, the amount of drugs delivered to the animals was
not exceeding clinically relevant concentrations.6 Animals
were monitored and weighed daily until the day of sacri-
ﬁce. The animals were sacriﬁced when body weight loss
was at least 10% compared with the initial body weight
(a condition referred to as ‘moderate cachexia’ based on
Evans et al.3), also in line with our previously published
ﬁndings.19 At time of sacriﬁce, no animals were excluded
from the study. Several tissues were collected, weighed,
snap frozen in liquid nitrogen, and stored at 80°C for fur-
ther studies. The tibialis anterior muscle was frozen in liq-
uid nitrogen-cooled isopentane, mounted in Optimal
Cutting Temperature medium, and stored for morphological
analyses. Total blood was withdrawn from anaesthetized
mice by cardiac puncture and collected in heparinized
tubes. To separate plasma from the haematocrit, all the
blood was centrifuged in a haematocrit centrifuge for
15 min at 3500 rpm.
Cell lines
Murine C26 cells were provided by Donna McCarthy (Ohio
State University) and cultured in high glucose (4.5 g/L)
Dulbecco’s modiﬁed Eagle’s medium supplied with 10%
foetal bovine serum, 1% glutamine, 1% sodium pyruvate,
and 1% penicillin/streptomycin. Cells were maintained in a
5% CO2, 37°C humidiﬁed incubator.
Muscle grip strength
The evaluation of the whole body strength in mice was
assessed as described in Bonetto et al.20 A forelimb grip
strength blinded test was performed at Day 14 after tumour
implantation by using a commercial digital grip strength
dynamometer (Columbus Instruments, Columbus, OH, USA).
Overall, ﬁve measurements were completed, and only the
top three measurements (peak force, expressed in grams)
were included in the analysis.20
Muscle cross-sectional area
Ten-micrometre-thick cryosections of tibialis anterior muscles
taken at the mid-belly were incubated overnight with poly-
clonal anti-laminin (1:1000; Sigma-Aldrich) to label the base-
ment membranes of the muscle cells.20 Sections were then
incubated for 1 h with Alexa Fluor 594-conjugated secondary
goat anti-rabbit IgG (Invitrogen, Carlsbad, CA, USA). All
samples were observed under an Axio Observer.Z1 motorized
microscope (Zeiss, Oberchoken, Germany), and images were
recorded for morphometric examination. For determination
of the cross-sectional area, muscle ﬁbre size (n = 300–500
per sample) was measured by using the ImageJ 1.43
software.
Quantiﬁcation of LDL receptor in liver and skeletal
muscle homogenates
The levels of LDL receptor were measured in liver and skeletal
muscle homogenates from all groups by using a speciﬁc ELISA
kit (#MLDLR0; Bio-Techne Corporation, Minneapolis, MN,
USA), according to the manufacturers protocol.
Enzymatic activity
The enzymatic activities of hexokinase, pyruvate dehydroge-
nase (PDH), citrate synthase (CS), and succinate dehydroge-
nase (SDH) were measured using Colorimetric Assay Kits
(#MAK091, MAK183, #CS0720, #MAK051, and #MAK197,
respectively) from Sigma-Aldrich according to the manufac-
turer’s instruction. Brieﬂy, 10 mg of skeletal muscle tissue
was homogenized in 100 μL of ice-cold assay buffer and then
centrifuged, and 10 μL of homogenate was added to 96-well
plates. Appropriate reaction mix was added to each of the
wells and the product of enzyme reaction, which results in
a colorimetric (600 nm for SDH, 450 nm for hexokinase, Acon,
and PDH, and 412 nm for CS) product proportional to the en-
zymatic activity. The absorbance was recorded by incubating
the plate at 37°C taking measurements (600, 450, or 412 nm)
every 5 for 30 min.
Sample preparation for nuclear magnetic
resonance
Plasma samples for NMR analysis were prepared diluting
100 μL of plasma with 500 μL of a deuterated phosphate
buffer solution (pH = 7.4) containing 2,2,-dimethyl-2-
silapentane-5-sulfonate sodium salt (DSS) with a ﬁnal concen-
tration of 0.5 mM to be used as a chemical shift and quanti-
tation reference. The solution was then ﬁltered through a
10 KDa molecular weight cut-off ﬁlter to remove the proteins.
Samples were placed in 5 mm NMR tube for analysis. Muscle
and liver tissues for NMR analysis were prepared according to
the methanol/chloroform water procedure described by
Beckonert et al.21 (Nature Protocols, 2, 2692, 2007). Tissue
samples of ~100 mg were used for all sample, but actual
weights were recorded to normalize the data.
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Sample preparation for mass spectrometry
Samples for targeted mass spectrometry analysis were con-
ducted using the Biocrates AbsoluteIDQ kit (Biocrates, Inns-
bruck, Austria). Each plate contains 16 wells reserved for
selected internal standards to optimize the metabolite
quantiﬁcation. For serum analysis, 10 μL aliquots were
loaded directly into the 96-well plate followed by derivatiza-
tion and extraction per vendor protocols. Muscle and liver
tissue were prepared according to vendor protocols
(Biocrates, Preparation of Tissue and Feces Samples for Met-
abolic Phenotyping, version 1.0).
Nuclear magnetic resonance data collection
Nuclear magnetic resonance data were acquired on a Bruker
Avance III 700 MHz NMR spectrometer with a TXI triple reso-
nance probe operating at 25°C. Spectra were collected with a
1D NOESY pulse sequence covering 12 ppm. The spectra were
digitized with 32 768 points during a 3.9 s acquisition time.
The mixing time was set to 100 ms, and the relaxation delay
between scans was set to 2.0 s.
Nuclear magnetic resonance lipoprotein proﬁling
Determination of lipoprotein particle subfractions by NMR
was assessed using the NMR-based platform at LipoScience
(now LabCorp, Morrisville, NC, USA). Lipoprotein particle
numbers and sizes were determined using a version of the
LP2 algorithm22 modiﬁed for murine plasma. GlycA levels
were quantiﬁed as described by Otvos et al.23
Nuclear magnetic resonance data processing
The data were processed using Advanced Chemistry Devel-
opment Spectrus Processor (version 2016.1; Toronto,
Canada). The spectra were zero ﬁlled to 65 536 points
and apodized using a 0.3 Hz decaying exponential function
and fast Fourier transformed. Automated phase correction
and third-order polynomial baseline correction were ap-
plied to all samples. Metabolite concentrations were quan-
tiﬁed using the Chenomx NMR Suite (version 8.2;
Edmonton, Canada). The DSS-d6 was used as a chemical
shift and quantiﬁcation reference for all spectra and was
set to a chemical shift of 0.00 and a concentration of
500 μM. Quantitative ﬁtting of each spectrum was carried
out in batch mode, followed by manual adjustment for
some spectra to correct for errors arising from spectral
overlap. For tissue samples, the ﬁnal concentrations were
normalized based on the weight of the tissue used to pre-
pare each sample. The quantiﬁcation of glycogen in muscle
and liver tissue was carried out using spectral integration
rather than spectral ﬁtting with the Chenomx software.
As glycogen is a heterogeneous polysaccharide of different
chain lengths, the NMR signals are composed of overlap-
ping peaks in speciﬁc windows of the spectrum. The inte-
gration range from 5.37 to 5.43 ppm was used, and the
concentrations are given in spectral intensity units.
Mass spectrometry data collection
This Biocrates AbsoluteIDQ p180 assay quantiﬁes 188 metab-
olites from six chemical classes: acylcarnitines (ACs), amino
acids, biogenic amines, hexoses (sum of hexoses), PCs, and
sphingomyelins. Data were collected on an AB Sciex 4000
QTRAP coupled to an Acquity UPLC system with the selective
mass-spectrometric detection using multiple reaction
monitoring pairs. The amino acids and biogenic amines were
detected using a liquid chromatography tandem mass spec-
trometry method, and the lipid species were detected using
a ﬂow injection analysis tandem mass spectrometry method
per vendor-deﬁned settings.
Mass spectrometry data analysis
Data analysis including normalization (tissue weight) for
quantiﬁcation of metabolite concentrations and quality
assessment was performed with the MetIDQ software
package, which is an integral part of the AbsoluteIDQ kit.
The metabolite concentration of each metabolite in each
experimental condition was compared with the measure-
ment detection limit speciﬁcations as reported by the
manufacturer of the AbsoluteIDQ p180 kit (Biocrates). A
metabolite was excluded from further analyses if its concen-
tration measurement data did not meet all of the following
criteria: (i) minor of 20% of missing values (non-detectable
peak) for each quantiﬁed metabolite in each experimental
group and (ii) 50% of all measured sample concentrations
for the metabolite had to be above the limit of detection.
Reactive oxygen species analysis
Reactive oxygen species (ROS) were detected using the 2,7-
dichloroﬂuorescein diacetate (DCFH-DA) as a probe. Brieﬂy,
gastrocnemius muscles were homogenized in 1.5 mL of
Milli-Q H2O. Muscle homogenates were then centrifuged
6 min at 13 000 rpm at 4°C and the supernatant collected.
For each sample, a 10 μL aliquot was mixed with 10 μL of
a 5 μM solution of DCFH-DA. After 15 min of incubation at
37°C, 1 mL of cold reaction buffer (0.1 M KPO4, pH 7.4,
0.1% (v/v) Triton X-100) was added to each sample and
kept on ice. DCFH-DA ﬂuorescence was detected by using
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ﬂuorimeter (488 nm ex/525 nm em). The data expressed as
arbitrary unit were normalized for the total protein
content.
Real-time quantitative polymerase chain reaction
RNA from quadriceps was isolated using the miRNeasy
Mini Kit (Qiagen, Valencia, CA, USA) and following the
protocol provided by the manufacturer. RNA was quanti-
ﬁed by using a Synergy H1 spectrophotometer (BioTek,
Winooski, VT, USA). RNA integrity was checked by electro-
phoresis on 1.2% agarose gel containing 0.02 mol/L
morpholinopropanesulfonic acid and 18% formaldehyde.
Total RNA was reverse transcribed to cDNA by using the
Verso cDNA kit (Thermo Fisher Scientiﬁc, Waltham, MA,
USA). Transcript levels were measured by real-time PCR
(Light Cycler 96, Roche, Indianapolis, IN, USA) taking ad-
vantage of the TaqMan gene expression assay system (Life
Technologies, Carlsbad, CA, USA). In particular, expression
levels for phosphoenolpyruvate carboxykinase (PEPCK;
Mm00551411_m1) were detected. Gene expression was
normalized to TATA-binding protein (Mm01277042_m1)
levels using the standard 2ΔCT methods.
Statistics
Statistical comparison of metabolites for each of the groups
was carried out in GraphPad Prism (GraphPad, La Jolla, CA,
USA) using a one-way analysis of variance with Tukey’s multi-
ple comparison test.
Results
Cancer and chemotherapy both induce reductions
in skeletal muscle mass and function
The in vivo models of cancer-induced and chemotherapy-
induced cachexia all demonstrate signiﬁcant alterations in
body composition and function. The four groups in this study
will be referred to as vehicle (V), cancer cachexia (CC), Folﬁri
treated (F), and cancer cachexia treated with Folﬁri (CCF).
Figure 1A shows the body weight changes observed for each
of the four groups, while Figure 1B shows the absolute
changes in body weight in the groups. The F group received
the ﬁrst treatment on Day 5, and after an initial increase in
body weight, starting Day 12 they exhibited a slow decline
in weight until sacriﬁce at Day 37, in accordance with our pre-
viously published observations.6 The CC group displayed a
rapid and precipitous decline in weight starting near Day 8
until sacriﬁce at Day 13.18 The CCF group had a similarly dra-
matic decline in body weight as the CC group, although their
overall survival was improved following the administration of
chemotherapy. Because of this, the size of the tumour in the
CCF group was signiﬁcantly larger than in the CC group
(Figure 1C). Muscle weight was signiﬁcantly reduced in the
CC and F groups, while, consistent with a larger tumour size,
it was signiﬁcantly exacerbated in the CCF group (Figure 1D).
In a similar manner, adipose tissue was signiﬁcantly depleted
in the CCF animals, while fat loss was more moderate in the
CC and F groups (Figure 1E). Consistent with a depletion of
muscle mass, a reduction in muscle grip strength (Figure 1F)
and a decrease in muscle ﬁbre cross-sectional areas
(40–50% vs. V) in the three experimental groups (Figure
1G) were also detected.
Plasma metabolome indicates difference in cellular
energetics with cancer cachexia and chemotherapy
A multiplatform metabolomics approach was conducted to
look for differences in the major cellular energy pathways.
Figure 2 shows several metabolites representative of glycoly-
sis and the TCA cycle. A signiﬁcant decrease in circulating glu-
cose of nearly 50% was observed in the CC group. A trend of
reduced plasma glucose of around 30% was observed for
both the F and CCF groups (P-values = 0.08 for each group
compared with vehicle). These data indicate an overall in-
crease in glucose consumption or alternatively a signiﬁcant
decrease in glucose production. At the end of the glycolytic
pathway, the pyruvate levels were not statistically different
from V, but the reduction in the CC group came close with
a P-value = 0.06. The lactate concentrations in each of the
experimental groups were not signiﬁcantly different from V,
although the level in the CCF group was signiﬁcantly higher
than in CC. This suggests some degree of drug-induced
mitochondrial stress, which would lead to an accumulation
of lactate.
The levels of citrate and succinate in the TCA cycle showed
dramatic alterations. In the CC group, both of these metabo-
lites were reduced by around 80%, consistent with a
decreased ﬂux through the TCA cycle. In contrast, the citrate
and succinate levels in the F group were not signiﬁcantly
different from the V group. The reductions in the CCF group
were consistent with the CC group suggesting that the
cancer-induced cachexia plays a dominant role in TCA
cycle ﬂux.
Differences in branched chain amino acid and fatty
acid oxidation in cancer cachexia and
chemotherapy
The levels of branched chain amino acids (BCAAs) presented
an interesting difference between the CC and F groups
(Figure 3A). In particular, the levels of isoleucine and valine
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were signiﬁcantly reduced in the CC group, while for all three
BCAAs, the levels were higher in the F group than in the CC
animals. This suggests clear differences in the amino acid ca-
tabolism and oxidation pathways. In the CCF group, the ad-
ministration of chemotherapy appears to provide some
level of recovery of the BCAA levels to those in the V group.
Acylcarnitines are formed from a family of carnitine
acyltransferases that exchange a CoA group for a carnitine.
AcylCoA species cannot cross the mitochondrial membrane,
but the ACs can. Once inside the mitochondria, these
transferases can shuttle the ACs out of the mitochondria
into the circulation. Serum ACs are thus a useful metabolic
surrogate for intermediates along the β-oxidation pathway.
Figure 3B shows the three shortest ACs. The C0 species is
carnitine with no fatty acid attached. The levels of C0 are
expected to increase with the concentration of fatty acids
in the blood to facilitate transport into the mitochondria for
fatty acid oxidation. The reduced level in the CC group may
indicate lower levels of fatty acids in the blood or simply
reduced fatty acid entry into the mitochondria. In the F
group, the levels were not signiﬁcantly different from V.
The CCF group displayed an intermediate level.
The C2 species is acetylcarnitine, which is in equilibrium
with acetyl-CoA. In all three experimental groups, the levels
were lower, which would be consistent with reduced
acetyl-CoA production, but the reduction was more
pronounced in the CC and CCF groups. The C3 species
(propionyl carnitine) can be derived from oxidation of fatty
acids and BCAAs. The comparatively higher levels of C3 in
the F group compared with the CC and CCF groups demon-
strated altered ﬂux of fatty acids and/or BCAAs through the
β-oxidation pathway. The levels of selected medium and
long chain ACs are shown in Figure 3C. These data suggest
a trend of reduced ﬂux through β-oxidation in both the CC
and F groups with the exception of the increased level of
the C8 AC in the CCF group.
Large changes in lipoprotein metabolism in cancer
cachexia
One of the most striking ﬁndings was a dramatic increase
in the number of low-density lipoprotein particles (LDL-Ps)
in the CC and CCF groups. Figure 4A shows that the LDL-
Figure 1 Morphological and functional changes associated with cancer-induced and chemotherapy-induced cachexia. Body weight (BW) curves (A)
and BW change (B) in vehicle-treated animals (V), C26 hosts (CC), Folﬁri-treated mice (F), or Folﬁri-treated tumour bearers (CCF). Tumour size mea-
sured at sacriﬁce in CC and CCF groups (C). Gastrocnemius (GSN), tibialis anterior (TA), and quadriceps (Quad) muscle weights (D). Liver, spleen,
and fat weights (E). All tissues and organs were normalized to the initial body weight (IBW) and expressed as weight/100 mg IBW. Whole body fore-
limb voluntary grasping strength, measured 13 days after tumour inoculation reported as peak force, was measured by taking advantage of a grip
strength metre and expressed as the average of the three top pulls from each animal (F). Quantiﬁcation of the cross-sectional area (CSA) in TA and
representative images obtained after immunoﬂuorescence staining of TA muscle cross sections for laminin (red) (G). Data are expressed as
means ± standard deviation. Statistical signiﬁcance was evaluated by two-way analysis of variance, and signiﬁcant differences (at least P < 0.05) were
reported as
a
P vs. V;
b
P vs. CC;
c
P vs. F.
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P particle numbers in the CC group were more than seven-
fold higher than the V group. An increase of 2.6-fold was
observed for the F group, although this difference did not
reach signiﬁcance. The effect appears to be additive yield-
ing an increase of 8.6-fold in the CCF group. As shown in
Figure 4B, the small-dense LDL-Ps appeared to be the
major components of this increased LDL particle count.
The HDL-P levels shown in Figure 4C showed a much less
dramatic reduction in HDL-P in the CC group, although this
was not signiﬁcant.
In order to clarify whether there was altered uptake of LDL
particles from the blood, LDL-receptor levels in muscle and
liver were quantiﬁed (Supporting Information, Figure S1).
Interestingly, the levels of the muscle LDL receptor were up-
regulated in all of the experimental groups with larger
increases in the CC and CCF groups (Supporting Information,
Figure S1A), while no signiﬁcant change was observed in the
liver (Supporting Information, Figure S1B). This indicates that
the observed effects are not simply due to decreased uptake
in the muscle.
Increased inﬂammation in cancer cachexia
Another blood-based biomarker that was measured is an
aggregate signal of N-acetyl glycan groups primarily at-
tached to acute phase proteins called GlycA.22 This bio-
marker has been associated with various inﬂammatory
conditions including arthritis, coronary heart disease,
and colorectal cancer. In our study, the levels of GlycA
were signiﬁcantly increased by around 30% in the CC
and CCF groups but not in the F group (Figure 5A). This
is consistent with an expected inﬂammatory state
with cancer cachexia and a lack of inﬂammation with
chemotherapy.
Figure 3 Plasma metabolites involved in amino acid and fatty acid me-
tabolism. Leucine (Leu), isoleucine (Iie), and valine (Val) levels (expressed
in mM) in the plasma of vehicle-treated animals (V), C26 hosts (CC),
Folﬁri-treated mice (F), or Folﬁri-treated tumour bearers (CCF) (A). Free
carnitine (C0), acetylcarnitine (C2), acylcarnitine (C3), octanoylcarnitine
(C8), decanoylcarnitine (10), and palmitoylcarnitine (16) levels (expressed
in mM) in the plasma of vehicle-treated animals (V), C26 hosts (CC),
Folﬁri-treated mice (F), or Folﬁri-treated tumour bearers (CCF) (B). Data
are expressed as means ± standard deviation. Statistical signiﬁcance
was evaluated by two-way analysis of variance, and signiﬁcant differ-
ences (at least P < 0.05) were reported as aP vs. V; bP vs. CC; cP vs. F.
Figure 4 Lipoprotein levels in the plasma of animals bearing cancer or
exposed to chemotherapy. Low-density lipoprotein-particle (LDL-P, A),
short-dense low-density lipoprotein-particle (sdLDL-P, B), and high-den-
sity lipoprotein-particle (HDL-P, C) levels (expressed in mM) in the plasma
of vehicle-treated animals (V), C26 hosts (CC), Folﬁri-treated mice (F), or
Folﬁri-treated tumour bearers (CCF). Data are expressed as means ± stan-
dard deviation. Statistical signiﬁcance was evaluated by two-way analysis
of variance, and signiﬁcant differences (at least P < 0.05) were reported
as
a
P vs. V;
b
P vs. CC;
c
P vs. F.
Figure 2 Glycolysis and tricarboxylic acid (TCA) cycle plasma intermedi-
ates are affected by cancer and chemotherapy. Representative diagram
of glycolysis and TCA cycle showing the metabolites concentration
(expressed in mM) detected in the plasma of vehicle-treated animals
(V), C26 hosts (CC), Folﬁri-treated mice (F), or Folﬁri-treated tumour
bearers (CCF). Data are expressed as means ± standard deviation. Statis-
tical signiﬁcance was evaluated by two-way analysis of variance, and sig-
niﬁcant differences (at least P < 0.05) were reported as aP vs. V; bP vs.
CC;
c
P vs. F.
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Cancer cachexia and chemotherapy both lead to
increased skeletal muscle reactive oxygen species
Oxidative stress is thought to play a role in both cancer
cachexia and some of the adverse effects of chemotherapy.
In order to evaluate this, we used 20,70-dichloroﬂuorescin
diacetate as a probe to measure the ROS in skeletal muscle.
Figure 5B shows that the ROS levels in the F and CCF groups
were signiﬁcantly increased and the level trended higher with
a P-value of 0.06 for the CC group. These data are consistent
with previously published evidence.6
Muscle metabolome shows overall decline in
energy metabolism
The next step in the investigation was to understand the
metabolic effects in the skeletal muscle by examining the
metabolic proﬁles of quadriceps muscle in mice bearing
cancer or exposed to chemotherapy. Figure 6 shows the
levels of several metabolites from the glycolysis and TCA
cycle pathways. A composite measurement of glycogen in
the muscle suggested no signiﬁcant differences in the carbo-
hydrate demands in the experimental groups. To further
evaluate any potential alterations in glycolysis in muscle, we
measured the enzymatic activity of hexokinase, the ﬁrst step
in the glycolytic pathway (Figure 7A). The activity levels were
consistent with V in the CC and F groups but signiﬁcantly
reduced in the CCF group.
The consistent levels of lactate across all groups suggest
pyruvate is still entering into the TCA cycle in the muscle. In
order to evaluate the entry of pyruvate into the TCA cycle,
Figure 5 Circulating glycoprotein acetylation (GlycA) and muscle reactive
oxygen species (ROS) levels. Circulating GlycA marker levels (expressed in
mM) (A) and ROS levels (expressed in arbitrary units, AU) (B) in the skel-
etal muscle of vehicle-treated animals (V), C26 hosts (CC), Folﬁri-treated
mice (F), or Folﬁri-treated tumour bearers (CCF). Data are expressed as
means ± standard deviation. Statistical signiﬁcance was evaluated by
two-way analysis of variance, and signiﬁcant differences (at least
P < 0.05) were reported as aP vs. V; bP vs. CC; cP vs. F.
Figure 6 Muscle glycolysis and tricarboxylic acid (TCA) cycle intermediates are affected by cancer and chemotherapy. Representative diagram of gly-
colysis and TCA cycle showing the metabolite concentration (expressed in mM) detected in the skeletal muscle of vehicle-treated animals (V), C26
hosts (CC), Folﬁri-treated mice (F), or Folﬁri-treated tumour bearers (CCF). Data are expressed as means ± standard deviation. Statistical signiﬁcance
was evaluated by two-way analysis of variance, and signiﬁcant differences (at least P < 0.05) were reported as aP vs. V; bP vs. CC; cP vs. F.
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we measured the activity of the enzyme PDH. This enzyme
catalyses the transformation of pyruvate into acetyl-CoA. As
shown in Figure 7B, the activity of PDH in each of the
experimental groups was reduced by between 20 and 30%
indicating reduced ﬂux of glycolysis-derived pyruvate into
the TCA cycle.
A combination of enzymatic activity and metabolite mea-
surements were conducted to evaluate the ﬂux through the
TCA cycle. Despite the reduced entry of pyruvate into the
TCA cycle, the enzymatic activities for the next two steps
in the TCA cycle were not signiﬁcantly altered (Figure 7C).
Citrate synthase transforms oxaloacetate and acetyl-CoA
into citrate. Glutamate is an anapleurotic substrate for
the TCA cycle; that is, it can enter the cycle to replenish
any metabolites that may be lost due from biosynthetic
processes. Although not statistically signiﬁcant, the trend
of reduced glutamate in the experimental groups is also
consistent with a reduced TCA cycle ﬂux. The reduced
levels of succinate, particularly in F and CCF, were consis-
tent with decreased ﬂux through the TCA cycle. Similarly,
the enzymatic activity of SDH for each of the groups
(Figure 7D) further supports reduced TCA cycle ﬂux in the
experimental groups. Given that SDH is also a component
of the electron transport chain, this could also indicate a
decrease in oxidative phosphorylation.
Metabolic proﬁles from the BCAAs and fatty acid oxidation
pathways in the muscle are shown in Figure 8. Unlike in
plasma, the BCAA levels in muscle appear consistent across
the groups (Figure 8A). Figure 8B shows that the free
carnitine (C0) levels were also consistent, suggesting no
major differences in fatty acid entry into the mitochon-
dria. A trend of reduced acetylcarnitine (C2) levels was
observed in the CC group (P-value = 0.13), and a signiﬁ-
cant decrease was observed in the CCF group suggesting
an overall reduction in acetyl-CoA production. The C3
AC levels suggested a reduced ﬂux through β-oxidation
with the effect being signiﬁcant in the CCF group. No sig-
niﬁcant differences in the long and medium chain ACs
were observed for the CC group, but signiﬁcant reduc-
tions in C10 and C16 species were observed in both
the F and CCF groups. This suggested that chemotherapy
induces a more pronounced reduction in β-oxidation than
cancer cachexia.
The levels of three major energy-related metabolites
were measured in the muscle tissue and were consistent
with reduced energy production (Figure 9). A signiﬁcant re-
duction in adenosine triphosphate (ATP) was observed in
each of the experimental groups, along with a consistent
increase in adenosine monophosphate (AMP) levels in the
F group only. Another energy carrier, creatine phosphate,
was lower in each of the experimental groups, consistent
with reduced cellular energy production.
Figure 7 Muscle enzymatic activities. The enzymatic activities of hexo-
kinase (HK, A), pyruvate dehydrogenase (PDH, B), citrate synthase (CS,
C), and succinate dehydrogenase (SDH, D) in the skeletal muscle of ve-
hicle-treated animals (V), C26 hosts (CC), Folﬁri-treated mice (F), or
Folﬁri-treated tumour bearers (CCF) were expressed in milliunits/mL
(mU/mL). Data are expressed as means ± standard deviation. Statistical
signiﬁcance was evaluated by two-way analysis of variance, and signif-
icant differences (at least P < 0.05) were reported as aP vs. V; bP vs.
CC;
c
P vs. F.
Figure 8 Muscle metabolites involved in amino acid and fatty acid me-
tabolism. Leucine (Leu), isoleucine (Iie), and valine (Val) levels (expressed
in mM) in the skeletal muscle of vehicle-treated animals (V), C26 hosts
(CC), Folﬁri-treated mice (F), or Folﬁri-treated tumour bearers (CCF) (A).
Free carnitine (C0), acetylcarnitine (C2), acylcarnitine (C3),
octanoylcarnitine (C8), decanoylcarnitine (10), and palmitoylcarnitine
(16) levels (expressed in mM) in the muscle of vehicle-treated animals
(V), C26 hosts (CC), Folﬁri-treated mice (F), or Folﬁri-treated tumour
bearers (CCF) (B). Data are expressed as means ± standard deviation. Sta-
tistical signiﬁcance was evaluated by two-way analysis of variance, and
signiﬁcant differences (at least P < 0.05) were reported as aP vs. V; bP
vs. CC; cP vs. F.
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Liver metabolome suggests increased
gluconeogenesis and tricarboxylic acid cycle ﬂux
with chemotherapy
A signiﬁcant depletion in both liver glucose and glycogen in
each of the experimental groups, shown in Figure 10, was
consistent with an increased systemic demand for glucose.
A major function of the liver is to use non-carbohydrate
sources to generate additional glucose under conditions of
high glucose demand as would be expected with a malig-
nancy. The gluconeogenic process can use lactate and alanine
as precursors. The lactate levels were not signiﬁcantly altered
in the experimental groups, but there was a trend towards
Figure 10 Liver glycolysis/gluconeogenesis and tricarboxylic acid (TCA) cycle intermediates are affected by cancer and chemotherapy. Represen-
tative diagram of glycolysis and TCA cycle showing the metabolite concentration (expressed in mM) detected in the liver of vehicle-treated
animals (V), C26 hosts (CC), Folﬁri-treated mice (F), or Folﬁri-treated tumour bearers (CCF). Data are expressed as means ± standard deviation.
Statistical signiﬁcance was evaluated by two-way analysis of variance, and signiﬁcant differences (at least P < 0.05) were reported as
a
P vs. V;
bP vs. CC; cP vs. F.
Figure 9 Muscle energy metabolites. Adenosine triphosphate (ATP),
adenosine monophosphate (AMP), and creatine phosphate (CrtnP)
levels (expressed in mM) in the muscle of vehicle-treated animals
(V), C26 hosts (CC), Folﬁri-treated mice (F), or Folﬁri-treated tumour
bearers (CCF). Data are expressed as means ± standard deviation. Sta-
tistical signiﬁcance was evaluated by two-way analysis of variance, and
signiﬁcant differences (at least P < 0.05) were reported as aP vs. V; bP
vs. CC; cP vs. F.
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lower values in the CC group. For alanine, the trend for lower
levels in the CC group remained, but the trend was reversed
for the F and CCF groups.
In the TCA cycle, the levels of fumarate and malate ap-
peared to trend higher levels in the experimental groups,
but only the level of malate in the F group met statistical sig-
niﬁcance. The anapleurotic substrate glutamate also showed
higher levels in the experimental groups with the levels in
the F and CCF groups meeting statistical signiﬁcance. In con-
trast to the muscle, it appears that TCA cycle activity was in-
creased in the liver.
To further interrogate the gluconeogenic process, we mea-
sured the gene expression levels of PEPCK, a critical enzyme
that is activated in gluconeogenesis. Interestingly, a signiﬁ-
cant increase in liver PEPCK was only observed for the F
group (Supporting Information, Figure S2).
Discussion
The goal of this study was to provide a comprehensive meta-
bolomics investigation of the differences between cancer-
induced and chemotherapy-induced cachexia. Given that ca-
chexia is a severe form of energy imbalance, we focused
our analytical approaches on the major cellular energetic
pathways. By analysing samples from plasma, muscle, and
liver, we were able to construct a more holistic picture of
the energetic derangements that are associated with these
different types of cachexia.
Our results indicate that systemic glucose metabolism is
clearly impacted in both cancer-induced and
chemotherapy-induced cachexia. Circulating glucose levels
were reduced in all experimental groups. One possible fac-
tor contributing to the hypoglycaemia is reduced food in-
take. Although food intake was not monitored in our
study, in a recent study aimed at characterizing the func-
tional and metabolic impairments associated with the C26
cachexia model, Murphy et al. showed that control mice,
pair fed to severely cachectic C26 tumour-bearing mice,
had no signiﬁcant difference in muscle mass compared with
ad libitum fed control mice, despite signiﬁcantly reduced
food intake. This suggests that the changes observed in
the cancer hosts were primarily linked to the growth of
the C26 tumour.24 A recent study from our laboratory
showed only transient drops in food intake after initiation
of Folﬁri treatment, but no signiﬁcant differences in the av-
erage food consumption were observed over the entire ex-
perimental period.6 Although we cannot rule out a reduced
food intake leading to the hypoglycaemia in the CC group,
we do not expect this to be a factor in the F group. Addi-
tionally, the consistently reduced levels of liver glycogen in
all three groups support a state of increased glucose de-
mand in cachexia from both cancer and chemotherapy.
In a previous study from our laboratory comparing C26
tumour-bearing mice with mice on a calorie-restricted
diet equivalent to a 40% reduction in caloric intake, we
found a signiﬁcant increase in the concentration of serum,
β-hydroxybutyrate, a metabolite that would be expected to
increase under starvation conditions.25 No signiﬁcant
differences in the levels of serum β-hydroxybutyrate across
any of the three groups were observed suggesting that the
metabolic phenotype was not due to a dramatic reduction
in caloric intake.
Increased expression of the PEPCK gene in both groups is
consistent with an up-regulation of gluconeogenesis to ac-
commodate the increased systemic demand. In the case of
the CC group, it is reasonable to postulate that much of the
glucose is being consumed by the tumour. The source of
the increased glucose demand is not as clear in the F and
CCF groups, where the effect does not seem to be driven
by muscle metabolism. The stable levels of muscle glycogen
in the experimental groups suggest that glucose demand is
not signiﬁcantly altered. The steady lactate levels also indi-
cate that the muscles have not switched to a predominantly
glycolytic metabolism.
Analysis of the TCA cycle indicates some signiﬁcant differ-
ences associated with cancer-induced and chemotherapy-
induced cachexia. Very signiﬁcant reductions in the plasma
levels of citrate and succinate were observed in the CC group,
while no signiﬁcant changes were found in the F group. These
differences between groups are not found in the muscle tis-
sue with both the CC and F groups showing reduced ﬂux
through the TCA cycle as indicated by reduced activity of
PDH and SDH along with reduced levels of succinate. A reduc-
tion in PDH activity is expected under conditions of metabolic
stress, including nutrient deprivation and hypoxia wherein
PDH is inactivated by PDH kinases.26,27 The exact nature of
the metabolic stresses imposed by malignancy and
chemotherapy may be different, but they both lead to similar
inactivation of PDH.
A number of studies have indicated that the activity of the
TCA cycle is reduced in cachexia. A mass spectrometry-based
ﬂux analysis found that the TCA cycle ﬂux in muscle was
signiﬁcantly reduced in a Lewis lung carcinoma model of can-
cer cachexia.28 A recent proteomics study of muscle tissue
from our lab identiﬁed reduced expression of proteins related
to oxidative phosphorylation, TCA cycle, and glycolysis in both
C26 hosts and Folﬁri-treated mice,5 thus suggesting that al-
terations of mitochondrial function may play a relevant role
in causing muscle wasting in these conditions. This was also
consistent with our previous reports, showing that mitochon-
drial abnormalities generally occur following cancer growth4
or chemotherapy treatment.6
Interestingly, the liver showed the opposite effect with a
trend towards increased levels of the TCA cycle intermedi-
ates, fumarate, and malate along with the anapleurotic
amino acid glutamate. This increase in oxidative metabolism
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could be required to provide energy for the increase in gluco-
neogenesis and, in the case of the cancer cachexia group, an
increased production of acute phase proteins, in line with our
previous observations.19
Signiﬁcant reduction in the plasma levels of free amino
acids, in particular the BCAAs, has been observed in pa-
tients with cachexia.15,25,29 In addition to providing building
blocks for protein synthesis, BCAAs also play a role in signal
transduction pathways that modulate protein synthesis.30
Under conditions of starvation, the circulating levels of
BCAAs have been shown to increase along with a signiﬁ-
cant decrease in BCAA oxidation.31 Enhanced rates of BCAA
oxidation have been observed in whole body and skeletal
muscle during sepsis, trauma, and after endotoxin or tu-
mour necrosis factor treatment.32–34 It should be noted
that each of these conditions is associated with cachexia.
Interestingly, the F group had little change in circulating
BCAA levels, but some of that may be due to the smaller
extent of weight loss in that group. The CCF group had
very similar overall loss in body weight but even more
weight loss in gastrocnemius, tibialis, and quadriceps than
the CC group. The BCAA levels in the F group are all signif-
icantly higher than the CC group, which may indicate that
Folﬁri treatment confers a more starvation-like phenotype
where more BCAAs are released into the circulation before
oxidation. This would suggest that the cachexia induced by
Folﬁri may not be effectively treated with supplemental
amino acids or related metabolites.
In our study, the levels of BCAAs in the skeletal muscle
were rather stable across the four groups. This somewhat
surprising result may be a function of the particular tissue
that we analysed. The quadriceps is composed of predomi-
nantly type IIB muscle ﬁbres, which are fast twitch ﬁbres with
low oxidative and high glycolytic activity. This lower depen-
dence upon oxidative metabolism may be the cause of the
more stable BCAA levels. Future studies should look at the
metabolic proﬁles of other types of skeletal muscle.
A recent study of kidney cancer by Fukawa et al. found
that excessive fatty acid oxidation was a major driver of mus-
cle wasting in cancer cachexia and they suggest that mitiga-
tion of this excess may be a promising therapeutic
approach.17 By applying media from a highly cachexia-
inducing cancer cell line onto C2C12 cells, this group found
a dramatic increase in ACs indicative of increased fatty acid
oxidation. They followed these results with an in vivo model,
where they used etomoxir, a carnitine palmitoyl transferase 1
inhibitor to block fatty acid oxidation. They found signiﬁ-
cantly reduced levels of ACs along with a rescue of skeletal
muscle mass. In contrast, our data suggest that fatty acid ox-
idation is reduced in both the CC and F groups but to differ-
ent extents. It is interesting to note that the CC group
displays signiﬁcant hyperlipidaemia as evidenced by the dra-
matically elevated LDL particle numbers, while also having re-
duced levels of C0 indicating reduced ability of fatty acids to
enter the β-oxidation pathway. The hyperlipidaemia in the F
group is more moderate, and the C0 levels in this group are
not signiﬁcantly different from vehicle-treated controls. The
increased levels of ACs found in the study by Fukawa
et al.17 indicate increased ﬂux, but an increase in ACs can also
be the result of incomplete fatty acid oxidation due to mito-
chondrial overload as demonstrated in the high-fat-diet
model by Koves et al.35 In our study, the reduced levels of
ACs are consistent with reduced fatty acid oxidation, but
given the potential for both cancer and chemotherapy to
induce mitochondrial defects, the levels of ACs may also be
inﬂuenced by these defects leading to build-up of certain
ACs. The distinctly different AC proﬁles in the CC and F group
compared with kidney cancer model reported by Fukawa
et al.17 indicate that targeting a reduction in fatty acid oxida-
tion to combat these forms of cachexia is less promising.
Mitochondrial ATP synthesis has been shown to be se-
verely impaired in skeletal muscle in cancer cachexia.36
Our study shows reduced production of both muscle ATP
and creatine phosphate in the CC and F groups. Cachectic
muscle has been shown to have dysfunctions in the elec-
tron transport chain37 and increased expression of mito-
chondrial uncoupling proteins (UCPs).38–40 The UCPs
promote proton leak across the inner mitochondrial mem-
brane, reducing the proton gradient, generating heat, and
reducing the production of ATP. Both cancer and chemo-
therapy have been associated with increases in oxidative
stress, and in both cases, an up-regulation of UCPs may
be a compensatory mechanism to inhibit oxidative phos-
phorylation, thereby reducing oxidative stress.41,42 The
decreased levels of ATP can also induce a signalling cascade
that reduces protein synthesis. When the AMP/ATP ratio is
high, the adenosine monophosphate-activated protein
kinase (AMPK) is activated leading to downstream inhibi-
tion of mammalian target of rapamycin(mTOR)-mediated
protein synthesis.
Intravenous injection of ATP has been used in a clinical trial
on advanced non-small-cell lung cancer patients. In this
study, the cachectic patients receiving ATP experienced no
signiﬁcant weight loss, whereas those not receiving ATP lost
an average of 1.6 kg of body weight over a 1 month pe-
riod.43,44 Our results suggest that supplemental ATP may in-
deed provide some beneﬁt with both cancer-induced and
chemo-induced cachexia.
One of the most striking ﬁndings was the difference in the
lipoprotein alterations between the CC and F groups. Hyper-
lipidaemia, including increased levels of circulating free fatty
acids, triglycerides, and cholesterol, has been observed in
cancer cachexia and an earlier metabolomics study on the
C26 cachexia model reported elevations in VLDL and LDL
levels.15 An observation of increased LDL and decreased
HDL similar to that found here was found in end-stage renal
disease, and the proposed mechanism may shed some light
on what is happening in cachexia.45–47 Under normal
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circumstances, intermediate density lipoproteins (IDLs) are
converted to cholesterol ester-rich LDLs, which are cleared
by the liver via the LDL receptor. The conversion of IDL to
LDL involves the action of cholesterol ester transfer protein,
which exchanges triglycerides from the IDL with cholesterol
esters from HDL particles. End-stage renal disease is charac-
terized by reduced levels of HDL and by hepatic lipase deﬁ-
ciency. These abnormalities lead to the accumulation of
IDLs and formation of cholesterol-poor, triglyceride-rich,
small-dense LDL particles. These particles have lower afﬁnity
for LDL receptor; thus, despite the lack of change in the liver
LDL receptor and the increase in the muscle LDL receptor,
these small-dense LDL particles may remain in circulation be-
cause of reduced binding afﬁnity. This effect will be exacer-
bated by the continued reduction in skeletal muscle mass.
Further studies will be conducted to see if these mechanisms
are at play in cancer cachexia.
Our observation of oxidative stress in both cancer-
induced and chemotherapy-induced cachexia is concordant
with previous studies. Oxidative stress has been consis-
tently observed in experimental models of cancer cachexia.
Using the Yoshida AH-130 rat hepatoma model, Barreiro
et al. found increased levels of malondialdehyde, a decom-
position product of oxidized lipids, along with an associated
up-regulation of the ubiquitin proteasome system.48 Oxida-
tive stress is also found with many chemotherapeutics. In
fact, the primary mechanism of many chemotherapeutic
drugs involves the formation of ROS to kill the tumour.49
This can lead to an overall depletion of the endogenous an-
tioxidant defence systems. In skeletal muscle, exposure to
elevated antioxidants is known to cause muscle weakness
and accelerate the rate of fatigue.50,51 There is much de-
bate on whether antioxidant supplementation can alter
the efﬁcacy of chemotherapeutics, but a systematic review
found no evidence of antioxidant interference with chemo-
therapy mechanisms and a possibility that antioxidants may
even improve tumour response and patient survival.49 Anti-
oxidant treatment may therefore be beneﬁcial in both
treating the tumour and sparing the skeletal muscle dam-
age induced by the tumour, thereby enabling patients to
complete their therapeutic regimen and thus improve
survival.
The inﬂammatory marker GlycA presents a clear difference
between the CC and F groups. This NMR-detectable plasma
biomarker is an aggregate signal of acute phase glycoproteins
and has been observed to be higher in patients with inﬂam-
matory conditions such as diabetes, rheumatoid arthritis,52,53
cancer,52,54,55 and insulin resistance.56 It is well established
that the growth of the C26 tumour leads to a signiﬁcant in-
crease in interleukin-6 (IL-6) levels, which correlate with the
loss of body weight57 and lead to hepatic synthesis and secre-
tion of acute phase proteins.58 In a recent study of rheuma-
toid arthritis, GlycA was signiﬁcantly correlated with
circulating IL-6.59 Some chemotherapeutics, such as
cyclophosphamide-doxorubicin-5-ﬂuorouracil, can lead to in-
creases in IL-6 production, thus promoting changes in body
composition and fatigue.60 However, in our previous studies
conducted in Folﬁri-treated mice, no STAT3 phosphorylation
was observed, indicating that the STAT3/IL-6 pathway was
not directly involved in the muscle wasting observed follow-
ing Folﬁri administration.57 Thus, it appears that the lack of
alteration of GlycA in the F group is likely due to an insignif-
icant activation of the IL-6 pathway.
In cancer, the observation of systemic inﬂammation has
been associated with an increase in ubiquitin proteasome
mediated muscle wasting.61 The observations of increases
in the ubiquitin proteasome system with chemotherapy have
been inconsistent,6 further suggesting that, at least in the
case of Folﬁri, the inﬂammatory system is less involved.
This study revealed a number of critical differences in the
metabolic effects of cancer-induced and chemotherapy-
induced cachexia, but it is important to highlight the differ-
ences observed when chemotherapy is added to the cachexia
model. Some of the observed changes in the CCF group are
consistent with the changes observed in the other treatment
groups. For example, the serum glucose levels as well as the
liver glucose and glycogen levels are consistently reduced in
all treatment groups. Many of the most signiﬁcant metabolic
effects observed in the CCF group are close to the CC group
such as serum citrate, succinate, and short chain ACs, GlycA,
and LDL-P. These similarities may be due to the higher levels
of weight loss in these two groups. There are only few obser-
vations of metabolites where the CCF levels are closer to the
F group than the CC group. These include serum lactate,
muscle glycogen, and liver alanine. In each of these examples,
the CCF levels are, in fact, not different from the V group.
These observations, although subtle, demonstrate that some
chemotherapy-induced perturbations may be greater than
the cancer-induced perturbations.
Conclusions
The results of this comprehensive metabolic proﬁling
demonstrate that cancer-induced and chemotherapy-induced
cachexia is characterized by a number of common and
unique metabolic derangements. Both treatments led to an
up-regulated systemic glucose demand, with decreased
circulating glucose, and signiﬁcant depletion of liver glucose
and glycogen. Signiﬁcant differences between cancer and
chemotherapy were observed in amino acid catabolism and
ﬂux through the TCA cycle and β-oxidation pathways. Distinct
differences were also observed in lipoprotein metabolism and
inﬂammation. The results of this study make it clear that ther-
apeutic interventions for cachexia must take into account the
speciﬁc pathological or pharmacological driver of the ca-
chexia. Given the heterogeneity of cachectic phenotypes
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induced by cancer and chemotherapy, it must be recognized
that the results of this study may be unique to the speciﬁc
models used. New studies are underway with additional
cancer-induced and chemotherapy-induced models of
cachexia to further explore the common and unique meta-
bolic drivers of cachexia.
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